Remove Chemotherapy Remove Compounding Remove Labelling
article thumbnail

Pluvicto™ offers survival benefits for metastatic prostate cancer

European Pharmaceutical Review

PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Pluvicto is an intravenous radioligand therapy that combines a ligand, a targeting compound with lutetium-177, a therapeutic radionuclide.

article thumbnail

US FDA approves Incyte’s merkel cell carcinoma therapy

Pharmaceutical Technology

It is also being assessed in other tumour types and along with other Incyte pipeline compounds. Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. We continue to study the potential of Zynyz in additional tumour types and in combination with other Incyte pipeline compounds.”

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.

article thumbnail

MHRA approves Pluvicto® and Locametz® for prostate cancer

European Pharmaceutical Review

Radioligand therapy (RLT), which combines a targeting compound (ligand) with a therapeutic radioactive atom (radioisotope), is an emerging treatment approach that may offer an alternative treatment option for some cancer patients. Its licensing makes it the first diagnostic PSMA imaging tracer to receive this status in Great Britain.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?

article thumbnail

Ondansetron for dogs: Dosage and safety

The Checkup by Singlecare

In human patients, it’s used to treat vomiting and nausea due to cancer chemotherapy or radiation therapy. Veterinarians commonly use ondansetron for chemotherapy, but its use in dogs is “ off-label.” Nausea-inducing chemotherapy is a common reason veterinarians give dogs ondansetron. Can dogs overdose on ondansetron?

Dosage 52
article thumbnail

Ondansetron for cats: Dosage and safety

The Checkup by Singlecare

Ondansetron for cats is an extra-label use of the drug. The most common reasons ondansetron is needed in cats are chemotherapy, drug treatment, and pancreatitis (inflamed pancreas). Chemotherapy and drug-induced vomiting Like dogs and humans, cats can get malignant cancers that require chemotherapy.

Dosage 52